A citation-based method for searching scientific literature


List of co-cited articles
56 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


GLP-1 Agonists in Type 1 Diabetes Mellitus.
Kristin M Janzen, Taylor D Steuber, Sarah A Nisly. Ann Pharmacother 2016
17
27

The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis.
Heming Guo, Chen Fang, Yun Huang, Yufang Pei, Linqi Chen, Ji Hu. Diabetes Res Clin Pract 2016
33
27


Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3.
Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Margareth Afonso Torres. Endocrinol Diabetes Metab Case Rep 2016
14
18

GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?
Djordje S Popovic, Edita Stokic, Stevan L Popovic. Curr Pharm Des 2015
4
50

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
100
18

Predictors of increasing BMI during the course of diabetes in children and adolescents with type 1 diabetes: data from the German/Austrian DPV multicentre survey.
Elke E Fröhlich-Reiterer, Joachim Rosenbauer, Susanne Bechtold-Dalla Pozza, Sabine E Hofer, Edith Schober, Reinhard W Holl. Arch Dis Child 2014
65
18

Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study.
Lenna L Liu, Jean M Lawrence, Cralen Davis, Angela D Liese, David J Pettitt, Catherine Pihoker, Dana Dabelea, Richard Hamman, Beth Waitzfelder, Henry S Kahn. Pediatr Diabetes 2010
199
18



Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
Richard E Pratley, Michael A Nauck, Anthony H Barnett, Mark N Feinglos, Fernando Ovalle, Illana Harman-Boehm, June Ye, Rhona Scott, Susan Johnson, Murray Stewart,[...]. Lancet Diabetes Endocrinol 2014
213
18

A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
18

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide.
Tara Gurung, Deepson S Shyangdan, Joseph Paul O'Hare, Norman Waugh. Diabetes Metab Syndr Obes 2015
10
20

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus.
Andreas B Petersen, Mikkel Christensen. Diabetes Metab Syndr Obes 2013
27
18

Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
Lawrence A Leiter, Molly C Carr, Murray Stewart, Angela Jones-Leone, Rhona Scott, Fred Yang, Yehuda Handelsman. Diabetes Care 2014
57
18

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.
M A Bush, J E Matthews, E H De Boever, R L Dobbins, R J Hodge, S E Walker, M C Holland, M Gutierrez, M W Stewart. Diabetes Obes Metab 2009
123
18

The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes.
Tae Jung Oh, Min Young Kim, Ji Yon Shin, Jung Chan Lee, Sungwan Kim, Kyong Soo Park, Young Min Cho. Clin Endocrinol (Oxf) 2014
21
18


Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.
Mahesh M Umapathysivam, Michael Y Lee, Karen L Jones, Christopher E Annink, Caroline E Cousins, Laurence G Trahair, Chris K Rayner, Marianne J Chapman, Michael A Nauck, Michael Horowitz,[...]. Diabetes 2014
77
18


Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men.
Robert E Steinert, Joerg Schirra, Anne C Meyer-Gerspach, Philipp Kienle, Heiko Fischer, Felix Schulte, Burkhard Goeke, Christoph Beglinger. Am J Clin Nutr 2014
28
18

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Julio Rosenstock, Vivian A Fonseca, Jorge L Gross, Robert E Ratner, Bo Ahrén, Francis C C Chow, Fred Yang, Diane Miller, Susan L Johnson, Murray W Stewart,[...]. Diabetes Care 2014
164
18

Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.
Bo Ahrén, Molly C Carr, Karen Murphy, Christopher Perkins, Marc Rendell, Jason Mallory, Timothy Wilson, Susan Johnson. Diabetes Res Clin Pract 2017
10
20

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
M E J Lean, R Carraro, N Finer, H Hartvig, M L Lindegaard, S Rössner, L Van Gaal, A Astrup. Int J Obes (Lond) 2014
94
18

Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
Amy G Egan, Eberhard Blind, Kristina Dunder, Pieter A de Graeff, B Timothy Hummer, Todd Bourcier, Curtis Rosebraugh. N Engl J Med 2014
316
18

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.
Jessica E Matthews, Murray W Stewart, Erika H De Boever, Robert L Dobbins, Rebecca J Hodge, Susan E Walker, M Claire Holland, Mark A Bush. J Clin Endocrinol Metab 2008
138
18

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
A Astrup, R Carraro, N Finer, A Harper, M Kunesova, M E J Lean, L Niskanen, M F Rasmussen, A Rissanen, S Rössner,[...]. Int J Obes (Lond) 2012
327
18

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.
Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, June Ye, John J V McMurray. Lancet Diabetes Endocrinol 2015
53
18


Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus.
Joshua J Neumiller, R Keith Campbell. Ann Pharmacother 2009
42
18

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
Jennifer M Trujillo, Wesley Nuffer. Ann Pharmacother 2014
36
18



The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
18

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
18

Exenatide efficacy and safety: a systematic review.
S L Norris, N Lee, S Thakurta, B K S Chan. Diabet Med 2009
60
18


Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
Rhonda Bentley-Lewis, David Aguilar, Matthew C Riddle, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Peter Johnston, Lars V Køber, Francesca Lawson,[...]. Am Heart J 2015
60
18


Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes.
Andrea Mari, Jonatan I Bagger, Ele Ferrannini, Jens J Holst, Filip K Knop, Tina Vilsbøll. PLoS One 2013
22
18

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Michael Elashoff, Aleksey V Matveyenko, Belinda Gier, Robert Elashoff, Peter C Butler. Gastroenterology 2011
536
18

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
18

Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig.
C F Deacon, L Pridal, L Klarskov, M Olesen, J J Holst. Am J Physiol 1996
250
18



Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
M Nauck, F Stöckmann, R Ebert, W Creutzfeldt. Diabetologia 1986
864
18

Response to Comment on Crews et al. Role and Determinants of Adherence to Off-loading in Diabetic Foot Ulcer Healing: A Prospective Investigation. Diabetes Care 2016;39:1371-1377.
Ryan T Crews, Biing-Jiun Shen, Laura Campbell, Peter J Lamont, Matthew Hardman, Andrew J M Boulton, Mark Peyrot, Robert S Kirsner, Loretta Vileikyte. Diabetes Care 2016
16
18

Clinical pharmacology of albiglutide, a GLP-1 receptor agonist.
Malcolm A Young, Jeffrey A Wald, Jessica E Matthews, Rhona Scott, Rebecca J Hodge, Hui Zhi, Rickey R Reinhardt. Postgrad Med 2014
20
18

Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.
Philip J Larsen, Jens Juul Holst. Regul Pept 2005
72
18



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.